NH-7211 – a Broad Acting Anti-Alzheimer’s Compound
Novel small chemical compounds capable of disrupting the three key misfolded proteins responsible for Alzheimer’s disease (AD) and other CNS disorders Description
Our researchers have created novel small chemical compounds capable of disrupting the three key misfolded proteins responsible for Alzheimer’s disease (AD) and other CNS disorders. Our lead compound, NH-7211 has been extensively tested in both in vitro and in vivo models and has shown a unique ability to inhibit ABeta40/ABeta42, tau and alpha-synuclein aggregation. This data suggests that our researchers have created a class of compounds capable of modulating key regulatory domain(s) within these misfolding proteins.
In APP/PS1 transgenic AD mice, NH-7211 rescued long-term potentiation suggesting that it rescues memory deficits caused by ABeta40 formation. This key in vivo data is supported by cell culture studies showing that inhibition of ABeta40 formation significantly reduces hippocampal cell death. In addition, in vitro studies showed that NH-7211 effectively reduces ABeta40 aggregation in a dose-dependent manner (see figure1).
An independent contract laboratory company has conducted experiments studying the pharmacokinetic characteristics of NH-7211. Preliminary data suggests that NH-7211 possesses high blood brain barrier penetration and high bioavailability, which is consistent with its high metabolic stability. An initial high dose (300 mg/kg) in vivo rat study measuring functional toxicity and mortality was negative.
State of Development
Ongoing research includes additional in vivo APP/PS1 mouse studies, in vivo pharmacokinetic studies and additional medicinal chemistry work is being conducted to develop second and third generation analogues of NH-7211. Patent applications have been filed in various jurisdictions around the World.
PARTEQ Innovations, the technology transfer office of Queen’s University, is seeking industrial partners willing to support ongoing development of the product and/or who are interested in licensing the intellectual property.
Type of Offer:
« More Healthcare Patents« More Life Sciences Patents